PRAX Options Analysis: $11M Biotech LEAP Signals Clinical Catalyst Confidence
Biotech explosion alert: $11M LEAP call bet on PRAX ahead of Phase 3 data. Wall Street positioning for FDA approval catalyst. In-depth analysis covers clinical timeline, market opportunity, and risk management.
This post is for paying subscribers only
Already have an account? Sign in.